

Policy for Fighting against Counterfeits, Fakes and Substandard Drugs at Boehringer Ingelheim

Boehringer Ingelheim is committed to helping to address the growing problem of counterfeit medications and to protecting patients, within the meaning of Responsible Care, from the dangers presented by counterfeit medicines. Counterfeit or fake medicines present a growing problem with the opening of markets and the creation of common economic areas.

Definition

Counterfeit medicines

Boehringer Ingelheim accepts the definition of counterfeit medicine as promulgated by the WHO:

“A counterfeit medicine is one which is deliberately and fraudulently mislabelled with respect to identity and/or source.

Counterfeiting can apply to both branded and generic products and counterfeit products may include products with the correct ingredients or with the wrong ingredients, without active ingredients, with insufficient active ingredient or with fake packaging”

Initiatives

Boehringer Ingelheim commits its support to initiatives run by associations, law enforcement authorities and governments designed to fight the spread of counterfeit medicines.

Measures

Boehringer Ingelheim, according to the standards of the pharmaceutical industry, continually develops concepts and implements measures to impede the production of counterfeit copies of its products and to render its own products more readily distinguishable from fake products.

Boehringer Ingelheim has its own internal system for reporting and registering counterfeit medicines.

For example, production waste and goods that have passed their expiry date are treated and disposed of in full compliance with all applicable local laws, rules and regulations to minimize the risk of later misuse of the material.

Drug packaging is secured in different ways according to applicable rules and regulations, depending on the respective problem at hand. For example, tamper-evident markings or tamper-evident seals are considered and used where appropriate.

Communication with consultants, specialists and patients is also taken as an opportunity to develop measures to address counterfeiting of Boehringer Ingelheim drug products.

We cooperate actively with investigators and criminal prosecutors in an effort to prevent the sale of counterfeit products and to call those persons involved to account.


Responsibilities

BIGmbH (Headquarters) will work actively with its subsidiaries and affiliates to help assure that this policy is reflected in local initiatives in the countries and markets and for the relevant products; it also supports the local units in devising concepts and measures. BIGmbH will also actively defend its commercial patent rights when violated by cases of counterfeiting.

The local units register and report all cases of counterfeiting of which they become aware to BIGmbH and support the local associations, law enforcement authorities and governments in their measures aimed at fighting counterfeiting. Concepts are prepared and the necessary measures taken following consultation with BIGmbH.

Ingelheim, November 2001


The Board of Managing Directors




Prof. Dr. Dr. h.c. Rolf Krebs




Dr. Alessandro Banchi



Dr. Dr. Andreas Barner



Dr. Hans-Jürgen Leuchs



Prof. Dr. Marbod Muff